To choose the best method for creating sustained-release tablets, the trial formulations SR-001, SR-002, and SR-003 were used. The third formulation developed lumps during aqueous wet granulation, while the first two formulations had poor flow characteristics. After analyzing their flow characteristics, non-aqueous wet granulation was chosen as the best method. SR001, SR002, SR-003. Formulations are not compressed due to poor flow properties. In order to achieve a sustained-release profile, combinations of HPMC K4M and HPC LF and HPMC K4M and HPMC K100M were not successful, as shown by a comparison of the percentage release rates of formulations SR-004 and SR-005. Instead, a combination of HPMC K100 M and HPMC K15 M, which contains high-viscosity polymers, was used (1,00,000 cps and 15,000 cps for HPMC K 100M and HPMC K15M respectively). Three distinct formulations (SR-006, SR-007, and SR-008) that contained HPMC K 100 M and HPMC K 15 M in variable proportions were examined. Of these, formulation SR-008 had the highest similarity factor and lowest dissimilarity factor to the reference product in terms of dissolving profile. The melting point of propranolol hydrochloride is within range, according to the thermograms. Therefore, it may be said that the excipients and the drug do not interact. To better understand the drug release behavior, kinetic treatment was applied to the release rates obtained from the optimized formulations B.No. SR-007 and SR-008. Upon the application of different drug release model kinetics, it was found that B.No. SR-007 and B.No. SR-008 follow the Higuchi model which shows continuous drug release for sustained period of time.